Mary Beth Terry, Dallas R English, Jo L Freudenheim, Béatrice Lauby-Secretan, Susan M Gapstur
{"title":"根据激素受体状态,戒酒和乳腺癌风险分层。","authors":"Mary Beth Terry, Dallas R English, Jo L Freudenheim, Béatrice Lauby-Secretan, Susan M Gapstur","doi":"10.1186/s13058-024-01937-z","DOIUrl":null,"url":null,"abstract":"<p><p>Because alcohol consumption is an established cause of female breast cancer, understanding whether cessation affects risk is of public health importance. In a recent meta-analysis, compared with continuing consumption, the relative risk (RR) for cessation was 0.95 (95% confidence interval [CI] 0.88-1.01). Because intake of alcohol is more consistently associated with estrogen receptor positive (ER+) than negative (ER-) subtypes, we conducted a meta-analysis of alcohol cessation for ER-specific breast cancer risk using data from three cohort studies and one population-based case-control study (ER + n = 3,793; ER- n = 627) with information reported on cessation and ER status. Compared with continuing consumption, cessation was associated with lower risk of ER+ (RR = 0.88, 95%CI, 0.79-0.98) but not ER- (RR = 1.23, 95%CI, 0.98-1.55) breast cancer. These results suggest that, compared with continuing consumption, alcohol cessation may reduce ER + but not ER- breast cancer risk. However, research that considers duration of cessation is warranted.</p>","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"26 1","pages":"179"},"PeriodicalIF":7.4000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619338/pdf/","citationCount":"0","resultStr":"{\"title\":\"Alcohol cessation and breast cancer risk stratified by hormone receptor status.\",\"authors\":\"Mary Beth Terry, Dallas R English, Jo L Freudenheim, Béatrice Lauby-Secretan, Susan M Gapstur\",\"doi\":\"10.1186/s13058-024-01937-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Because alcohol consumption is an established cause of female breast cancer, understanding whether cessation affects risk is of public health importance. In a recent meta-analysis, compared with continuing consumption, the relative risk (RR) for cessation was 0.95 (95% confidence interval [CI] 0.88-1.01). Because intake of alcohol is more consistently associated with estrogen receptor positive (ER+) than negative (ER-) subtypes, we conducted a meta-analysis of alcohol cessation for ER-specific breast cancer risk using data from three cohort studies and one population-based case-control study (ER + n = 3,793; ER- n = 627) with information reported on cessation and ER status. Compared with continuing consumption, cessation was associated with lower risk of ER+ (RR = 0.88, 95%CI, 0.79-0.98) but not ER- (RR = 1.23, 95%CI, 0.98-1.55) breast cancer. These results suggest that, compared with continuing consumption, alcohol cessation may reduce ER + but not ER- breast cancer risk. However, research that considers duration of cessation is warranted.</p>\",\"PeriodicalId\":49227,\"journal\":{\"name\":\"Breast Cancer Research\",\"volume\":\"26 1\",\"pages\":\"179\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619338/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13058-024-01937-z\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-024-01937-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
由于饮酒是女性乳腺癌的既定原因,了解戒酒是否会影响风险对公共卫生具有重要意义。在最近的荟萃分析中,与持续消费相比,戒烟的相对风险(RR)为0.95(95%可信区间[CI] 0.88-1.01)。由于酒精摄入与雌激素受体阳性(ER+)亚型比阴性(ER-)亚型更一致地相关,我们使用三项队列研究和一项基于人群的病例对照研究(ER+ n = 3,793;ER- n = 627),并报告了戒烟和ER状态的信息。与继续服用相比,戒烟与ER+乳腺癌风险降低相关(RR = 0.88, 95%CI, 0.79-0.98),但与ER-乳腺癌风险降低无关(RR = 1.23, 95%CI, 0.98-1.55)。这些结果表明,与持续饮酒相比,戒酒可能会降低ER +,但不会降低ER-乳腺癌的风险。然而,考虑戒烟持续时间的研究是有必要的。
Alcohol cessation and breast cancer risk stratified by hormone receptor status.
Because alcohol consumption is an established cause of female breast cancer, understanding whether cessation affects risk is of public health importance. In a recent meta-analysis, compared with continuing consumption, the relative risk (RR) for cessation was 0.95 (95% confidence interval [CI] 0.88-1.01). Because intake of alcohol is more consistently associated with estrogen receptor positive (ER+) than negative (ER-) subtypes, we conducted a meta-analysis of alcohol cessation for ER-specific breast cancer risk using data from three cohort studies and one population-based case-control study (ER + n = 3,793; ER- n = 627) with information reported on cessation and ER status. Compared with continuing consumption, cessation was associated with lower risk of ER+ (RR = 0.88, 95%CI, 0.79-0.98) but not ER- (RR = 1.23, 95%CI, 0.98-1.55) breast cancer. These results suggest that, compared with continuing consumption, alcohol cessation may reduce ER + but not ER- breast cancer risk. However, research that considers duration of cessation is warranted.
期刊介绍:
Breast Cancer Research, an international, peer-reviewed online journal, publishes original research, reviews, editorials, and reports. It features open-access research articles of exceptional interest across all areas of biology and medicine relevant to breast cancer. This includes normal mammary gland biology, with a special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal covers preclinical, translational, and clinical studies with a biological basis, including Phase I and Phase II trials.